Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

J. Abu‐Raddad, Laith; Chemaitelly, Hiam; A. Butt, Adeel

doi:10.1056/nejmc2104974

Public

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Published in New England Journal of Medicine • May 5, 2021

Authors:

Laith J. Abu‐Raddad

Hiam Chemaitelly

Adeel A. Butt

Abstract

The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, a total of 385,853 persons had received at least one vaccine dose and 265,410 h...

Subject

Coronavirus disease 2019 (COVID-19)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

2019-20 coronavirus outbreak

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!